Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery.

International journal of molecular sciences - 13 Dec 2022

Kalinowski Piotr, Smyk Wiktor, Nowosad Małgorzata, Paluszkiewicz Rafał, Michałowski Łukasz, Ziarkiewicz-Wróblewska Bogna, Weber Susanne N, Milkiewicz Piotr, Lammert Frank, Zieniewicz Krzysztof, Krawczyk Marcin

Abstract excerpt

The severity of hepatic steatosis is modulated by genetic variants, such as patatin-like phospholipase domain containing 3 (PNPLA3) rs738409, transmembrane 6 superfamily member 2 (TM6SF2) rs58542926, and membrane-bound O-acyltransferase domain containing 7 (MBOAT7) rs641738. Recently, mitochondrial amidoxime reducing component 1 (MTARC1) rs2642438 and hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) rs72613567...

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 17-Hydroxysteroid Dehydrogenases
Share to Bariatric Surgery
Share to Fibrosis
Share to Liver
Share to Liver Cirrhosis
Share to Mitochondrial Proteins
Share to Non-alcoholic Fatty Liver Disease
Share to Oxidoreductases

Source

Open in PubMed Open full text

Identifiers

PMID: 36555467
DOI: 10.3390/ijms232415825
PMCID: PMC9781679

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery.PMID 36555467Read ↗

Genetic modulators of metabolic dysfunction-associated steatotic liver disease (MASLD) and their epistatic interactions: from in vitro and animal models to clinical outcomes.Semantic proximity Read ↗

PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.Semantic proximity Read ↗

The rs72613567: TA Variant in the Hydroxysteroid 17-beta Dehydrogenase 13 Gene Reduces Liver Damage in Obese Children.Semantic proximity Read ↗

Advances in the genetics of nonalcoholic fatty liver disease.Semantic proximity Read ↗

Genetics of alcoholic liver disease and non-alcoholic steatohepatitis.Semantic proximity Read ↗

Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications.Semantic proximity Read ↗

Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic TargetSemantic proximity Read ↗

Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and TherapeuticsSemantic proximity Read ↗

Relevance of PNPLA3, TM6SF2, HSD17B13, and GCKR Variants to MASLD Severity in an Egyptian Population.Semantic proximity Read ↗

Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17‐beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanismsSemantic proximity Read ↗

Update on NAFLD genetics: From new variants to the clinic.Semantic proximity Read ↗

Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.